235 related articles for article (PubMed ID: 32588471)
1. Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats.
Prukop T; Wernick S; Boussicault L; Ewers D; Jäger K; Adam J; Winter L; Quintes S; Linhoff L; Barrantes-Freer A; Bartl M; Czesnik D; Zschüntzsch J; Schmidt J; Primas G; Laffaire J; Rinaudo P; Brureau A; Nabirotchkin S; Schwab MH; Nave KA; Hajj R; Cohen D; Sereda MW
J Neurosci Res; 2020 Oct; 98(10):1933-1952. PubMed ID: 32588471
[TBL] [Abstract][Full Text] [Related]
2. Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).
Prukop T; Stenzel J; Wernick S; Kungl T; Mroczek M; Adam J; Ewers D; Nabirotchkin S; Nave KA; Hajj R; Cohen D; Sereda MW
PLoS One; 2019; 14(1):e0209752. PubMed ID: 30650121
[TBL] [Abstract][Full Text] [Related]
3. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
Chumakov I; Milet A; Cholet N; Primas G; Boucard A; Pereira Y; Graudens E; Mandel J; Laffaire J; Foucquier J; Glibert F; Bertrand V; Nave KA; Sereda MW; Vial E; Guedj M; Hajj R; Nabirotchkin S; Cohen D
Orphanet J Rare Dis; 2014 Dec; 9():201. PubMed ID: 25491744
[TBL] [Abstract][Full Text] [Related]
4. An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.
Attarian S; Vallat JM; Magy L; Funalot B; Gonnaud PM; Lacour A; Péréon Y; Dubourg O; Pouget J; Micallef J; Franques J; Lefebvre MN; Ghorab K; Al-Moussawi M; Tiffreau V; Preudhomme M; Magot A; Leclair-Visonneau L; Stojkovic T; Bossi L; Lehert P; Gilbert W; Bertrand V; Mandel J; Milet A; Hajj R; Boudiaf L; Scart-Grès C; Nabirotchkin S; Guedj M; Chumakov I; Cohen D
Orphanet J Rare Dis; 2014 Dec; 9():199. PubMed ID: 25519680
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A.
Attarian S; Young P; Brannagan TH; Adams D; Van Damme P; Thomas FP; Casanovas C; Kafaie J; Tard C; Walter MC; Péréon Y; Walk D; Stino A; de Visser M; Verhamme C; Amato A; Carter G; Magy L; Statland JM; Felice K
Orphanet J Rare Dis; 2021 Oct; 16(1):433. PubMed ID: 34656144
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy.
Sociali G; Visigalli D; Prukop T; Cervellini I; Mannino E; Venturi C; Bruzzone S; Sereda MW; Schenone A
Neurobiol Dis; 2016 Nov; 95():145-57. PubMed ID: 27431093
[TBL] [Abstract][Full Text] [Related]
7. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy.
Meyer zu Horste G; Prukop T; Liebetanz D; Mobius W; Nave KA; Sereda MW
Ann Neurol; 2007 Jan; 61(1):61-72. PubMed ID: 17262851
[TBL] [Abstract][Full Text] [Related]
8. Curcumin-cyclodextrin/cellulose nanocrystals improve the phenotype of Charcot-Marie-Tooth-1A transgenic rats through the reduction of oxidative stress.
Caillaud M; Msheik Z; Ndong-Ntoutoume GM; Vignaud L; Richard L; Favreau F; Faye PA; Sturtz F; Granet R; Vallat JM; Sol V; Desmoulière A; Billet F
Free Radic Biol Med; 2020 Dec; 161():246-262. PubMed ID: 32980538
[TBL] [Abstract][Full Text] [Related]
9. Skin Biopsy Findings in Patients With CMT1A: Baseline Data From the CLN-PXT3003-01 Study Provide New Insights Into the Pathophysiology of the Disorder.
Duchesne M; Danigo A; Richard L; Vallat JM; Attarian S; Gonnaud PM; Lacour A; Péréon Y; Stojkovic T; Nave KA; Bertrand V; Nabirotchkin S; Cohen D; Demiot C; Magy L
J Neuropathol Exp Neurol; 2018 Apr; 77(4):274-281. PubMed ID: 29408953
[TBL] [Abstract][Full Text] [Related]
10. Charcot-Marie-Tooth disease and related inherited neuropathies.
Murakami T; Garcia CA; Reiter LT; Lupski JR
Medicine (Baltimore); 1996 Sep; 75(5):233-50. PubMed ID: 8862346
[TBL] [Abstract][Full Text] [Related]
11. Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease.
Grandis M; Leandri M; Vigo T; Cilli M; Sereda MW; Gherardi G; Benedetti L; Mancardi G; Abbruzzese M; Nave KA; Nobbio L; Schenone A
Exp Neurol; 2004 Nov; 190(1):213-23. PubMed ID: 15473994
[TBL] [Abstract][Full Text] [Related]
12. Structural and Functional Abnormalities of the Neuromuscular Junction in the Trembler-J Homozygote Mouse Model of Congenital Hypomyelinating Neuropathy.
Scurry AN; Heredia DJ; Feng CY; Gephart GB; Hennig GW; Gould TW
J Neuropathol Exp Neurol; 2016 Apr; 75(4):334-46. PubMed ID: 26921370
[TBL] [Abstract][Full Text] [Related]
13. Motor axonal sprouting and neuromuscular junction loss in an animal model of Charcot-Marie-Tooth disease.
Ang ET; Schäfer R; Baltensperger R; Wernig A; Celio M; Oliver SS
J Neuropathol Exp Neurol; 2010 Mar; 69(3):281-93. PubMed ID: 20142762
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of PMP22 ameliorates myelin defects in iPSC-derived human organoid cultures of CMT1A.
Van Lent J; Vendredy L; Adriaenssens E; Da Silva Authier T; Asselbergh B; Kaji M; Weckhuysen S; Van Den Bosch L; Baets J; Timmerman V
Brain; 2023 Jul; 146(7):2885-2896. PubMed ID: 36511878
[TBL] [Abstract][Full Text] [Related]
15. A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients.
Fledrich R; Schlotter-Weigel B; Schnizer TJ; Wichert SP; Stassart RM; Meyer zu Hörste G; Klink A; Weiss BG; Haag U; Walter MC; Rautenstrauss B; Paulus W; Rossner MJ; Sereda MW
Brain; 2012 Jan; 135(Pt 1):72-87. PubMed ID: 22189569
[TBL] [Abstract][Full Text] [Related]
16. The diadenosine homodinucleotide P18 improves in vitro myelination in experimental Charcot-Marie-Tooth type 1A.
Nobbio L; Visigalli D; Mannino E; Fiorese F; Kassack MU; Sturla L; Prada V; De Flora A; Zocchi E; Bruzzone S; Schenone A
J Cell Biochem; 2014 Jan; 115(1):161-7. PubMed ID: 23959806
[TBL] [Abstract][Full Text] [Related]
17. Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot-Marie-Tooth disease in mice.
Klein D; Patzkó Á; Schreiber D; van Hauwermeiren A; Baier M; Groh J; West BL; Martini R
Brain; 2015 Nov; 138(Pt 11):3193-205. PubMed ID: 26297559
[TBL] [Abstract][Full Text] [Related]
18. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial.
Burns J; Ouvrier RA; Yiu EM; Joseph PD; Kornberg AJ; Fahey MC; Ryan MM
Lancet Neurol; 2009 Jun; 8(6):537-44. PubMed ID: 19427269
[TBL] [Abstract][Full Text] [Related]
19. PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models.
Zhao HT; Damle S; Ikeda-Lee K; Kuntz S; Li J; Mohan A; Kim A; Hung G; Scheideler MA; Scherer SS; Svaren J; Swayze EE; Kordasiewicz HB
J Clin Invest; 2018 Jan; 128(1):359-368. PubMed ID: 29202483
[TBL] [Abstract][Full Text] [Related]
20. A transgenic rat model of Charcot-Marie-Tooth disease.
Sereda M; Griffiths I; Pühlhofer A; Stewart H; Rossner MJ; Zimmerman F; Magyar JP; Schneider A; Hund E; Meinck HM; Suter U; Nave KA
Neuron; 1996 May; 16(5):1049-60. PubMed ID: 8630243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
